Lipid Nanoparticles Market

The lipid nanoparticle (LNP) raw materials market is projected to reach USD 395.0 million by 2031, up from USD 298.8 million in 2026, at a CAGR of 5.7%. In parallel, the LNP services market is projected to reach USD 309.2 million by 2031, up from USD 161.0 million in 2026, at a CAGR of 13.9%. Growth is supported by an expanding pipeline of mRNA, siRNA, gene-editing, and other nucleic acid therapeutics; increasing demand for high-purity ionizable lipids, PEG lipids, phospholipids, and cholesterol; and rising outsourcing of formulation development, process scale-up, analytical characterization, GMP manufacturing, and fill-finish activities. Continued innovation in biodegradable and organ-selective ionizable lipids, together with the need for reproducible and regulatory-ready LNP manufacturing, is expected to further support market expansion.

The global LNP raw materials market is highly consolidated, with Avanti Polar Lipids (Croda International) (US/UK), Merck KGaA (Germany), NOF Corporation (Japan), and Nippon Fine Chemical Co., Ltd. (Japan) among the leading suppliers. These companies compete on high-purity and GMP-grade lipid portfolios, proprietary ionizable-lipid technologies, custom lipid synthesis, regulatory documentation, capacity expansion, and technical support for LNP formulation. The LNP services market is more fragmented and fast-growing, with specialized CDMOs and integrated life-science suppliers expanding capabilities in formulation screening, process development, scale-up, GMP manufacturing, analytical services, and fill-finish for nucleic acid-based therapeutics.

To know about the assumptions considered for the study download the pdf brochure

Avanti Polar Lipids (Croda International) (US/UK)

Avanti Polar Lipids, part of Croda International, is a leading supplier of specialized lipids for LNP research and development. Its portfolio includes ionizable lipids, phospholipids, PEG lipids, cholesterol-related materials, and other high-purity lipid components for RNA delivery, gene therapy, and nanoparticle formulation. The company supports customers from early formulation research through translational development, offering extensive lipid chemistry expertise, analytical documentation, batch traceability, and technical support. Its broad catalog and established position in research and pharmaceutical lipids strengthen its role in the LNP raw materials market.

Merck KGaA (Germany)

Merck KGaA is a leading provider of both LNP raw materials and services. Through its life science business, the company supplies synthetic and GMP lipids, including ionizable and cationic lipids, PEGylated lipids, phospholipids, and synthetic cholesterol, as well as custom lipid development and manufacturing. Merck also offers integrated LNP contract services spanning early formulation screening, lipid manufacturing, LNP formulation and process development, GMP manufacturing, and fill-finish. This combination of raw-material supply and end-to-end development capabilities enables the company to support nucleic acid programs from preclinical development through commercialization.

NOF Corporation (Japan)

NOF Corporation is a major supplier of functional lipids and drug-delivery-system materials for nucleic acid and gene therapy applications. The company offers proprietary COATSOME® SS-series ionizable lipids, SUNBRIGHT® PEG lipids, phospholipids, and customized lipid synthesis for LNP formulations. NOF has emphasized development of biodegradable ionizable lipids, formulation proposal capabilities, and expansion of pharmaceutical raw-material manufacturing capacity. Its established use of PEG lipids in commercial vaccine applications and growing engagement with clinical-stage nucleic acid programs support its competitive position in the LNP raw materials market.

Nippon Fine Chemical Co., Ltd. (Japan)

Nippon Fine Chemical is an established pharmaceutical lipid supplier with a portfolio spanning high-purity phospholipids, cholesterol, PEG lipids, cationic and functional lipids, and lipid mixtures for LNP and liposome applications. The company also provides development and CDMO support, including lipid-composition studies, encapsulation-method evaluation, small-scale preparation, quality evaluation, GMP manufacturing, and supply of liposome- or LNP-related materials. Its in-house lipid manufacturing, GMP quality systems, regulatory support, and ongoing development of next-generation ionizable lipids position the company as a key supplier to advanced drug-delivery programs.

Market Ranking

The LNP raw materials market is highly consolidated, with Avanti Polar Lipids (Croda International), Merck KGaA, NOF Corporation, and Nippon Fine Chemical estimated to account for approximately 70% to 75% of global market revenues. Their positions are supported by established lipid manufacturing expertise, broad portfolios spanning multiple LNP components, high-purity and GMP-grade supply capabilities, regulatory documentation, custom synthesis, and long-standing relationships with pharmaceutical and biotechnology customers. Competitive differentiation is increasingly focused on proprietary ionizable lipids, scalable manufacturing, supply security, and the ability to support customers from formulation development through clinical and commercial production.

The remainder of the LNP raw materials market, accounting for approximately 25% to 30%, consists of specialty lipid manufacturers, regional suppliers, and emerging developers of novel ionizable and targeted lipid chemistries. These companies compete through custom synthesis, niche lipid libraries, specialized GMP capabilities, regional supply support, and technology partnerships. In parallel, the LNP services market has a broader competitive base of CDMOs and formulation specialists, creating opportunities for differentiated providers that can combine rapid formulation screening, robust scale-up, analytical characterization, GMP manufacturing, and regulatory support for increasingly diverse RNA and gene-therapy pipelines.

Related Reports:

Lipid Nanoparticles Market by Product (Ionizable lipids, Phospholipids, Neutral Lipids), Type (SLNs, NLCs), Molecule (siRNA, mRNA), Application, Service Type (Formulation Development, Manufacturing), End User, Region - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]